Seed, Pre-Seed
$250K – $2.5M
$300M
20+ companies
6 partners
Investment Thesis
Invests in innovative technologies and therapies for major global health challenges, including oncology and genetic therapies.
Meet the Team
Industry Focus
Invests In
Portfolio Companies (20)
2023
LimmaTech Biologics
Vaccine development company working to halt AMR and STI infections.
2022
Curevo Vaccine
Next-generation subunit vaccines, initially targeting varicella and shingles.
Memo Therapeutics
Antibody discovery platform, initially targeting Nipah virus, SARS-CoV-2, CMV and BKV.
2021
Antiva Biosciences
Novel non-surgical therapeutic candidate to treat pre-cancerous cervical lesions caused by HPV.
Pulmocide
Novel therapies for patients suffering from serious acute and chronic respiratory diseases.
Excision BioTherapeutics
CRISPR-based therapies for chronic viral infectious diseases such as HIV and hepatitis B.
2020
LakeShore Biopharma
LakeShore is scaling up undersupplied global health vaccines and developing new biologics.
ChromaCode
ChromaCode's HD-PCR technology enhances multiplexing capabilities on existing hardware.
Codagenix
Codagenix uses emerging computational and synthetic biology tools to rationally design vaccines.
54gene
54gene is using African genetic data to drive discoveries in drug and vaccine development.
- •Raising at Seed, Pre-Seed? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare, Other — the sectors they actively back.
- •Size your ask to their typical $250K – $2.5M check.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Glenn Rockman, Managing Partner.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Adjuvant Capital is a match for your startup
Upload your pitch deck to see how well you match with Adjuvant Capital and 10,000+ other investors.
Is this your profile? Request a correction or removal